Chaft, Jamie E. http://orcid.org/0000-0002-5838-9982
Oezkan, Filiz
Kris, Mark G.
Bunn, Paul A.
Wistuba, Ignacio I.
Kwiatkowski, David J. http://orcid.org/0000-0002-5668-5219
Owen, Dwight H.
Tang, Yan
Johnson, Bruce E.
Lee, Jay M.
Lozanski, Gerard
Pietrzak, Maciej
Seweryn, Michal
Byun, Woo Yul http://orcid.org/0000-0001-8686-638X
Schulze, Katja
Nicholas, Alan
Johnson, Ann
Grindheim, Jessica http://orcid.org/0000-0003-2149-1622
Hilz, Stephanie
Shames, David S.
Rivard, Chris
Toloza, Eric
Haura, Eric B.
McNamee, Ciaran J.
Patterson, G. Alexander
Waqar, Saiama N.
Rusch, Valerie W.
Carbone, David P. http://orcid.org/0000-0003-3002-1921
Waqar, Saiama N.
Shum, Elaine
Nagasaka, Misako
Koczywas, Marianna
Garon, Edward B.
Finley, David J.
Camidge, David R.
Carlisle, Jennifer W.
Blasberg, Justin D.
,
Article History
Received: 8 March 2022
Accepted: 21 July 2022
First Online: 12 September 2022
Change Date: 10 October 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41591-023-02627-7
Competing interests
: J.E.C. serves as an advisor to Genentech/Roche, AstraZeneca/MedImmune, Merck, Bristol Myers Squibb, Flame Biosciences, Janssen Oncology, Guardant Health, Regeneron/Sanofi and Novartis. She reports research funding from Genentech/Roche, Bristol Myers Squibb, AstraZeneca/MedImmune, Novartis and Merck. F.O. reports honoraria from Novartis, serves as an advisor to Epigenomics, Sanofi-Aventis and Decibio and has received travel, accommodations and expenses from Genentech/Roche and research funding (paid to her institution) from Genentech/Roche. M.G.K. reports speaking fees from AstraZeneca and Pfizer, consultant fees from Janssen and in-kind support for medical writing from Hoffman La Roche. P.A.B. is on advisory or data safety monitoring boards for Bristol Myers Squibb and Merck and reports membership on the Board of Directors for Verastem, with funding paid to his institution. I.I.W. reports grants and personal fees from Genentech/Roche, Bayer, Bristol Myers Squibb, AstraZeneca, Pfizer, HTG Molecular, GlaxoSmithKline, Guardant Health, Merck, Novartis, Sanofi and Amgen; personal fees from Asuragen, Flame, Daiichi Sankyo, Oncocyte, MSD and Platform Health; and grants from Adaptive, Adaptimmune, EMD Serono, Takeda, Karus, Johnson & Johnson, 4D, Iovance and Akoya, outside of the submitted work. D.J.K. serves as an advisor to AstraZeneca and Genentech/Roche and reports research funding from AADi, Genentech and Revolution Medicines. D.H.O. reports funding (paid to his institution) from Genentech, Merck, Pfizer, Palobiofarma and Bristol Myers Squibb. Y.T. reports no relationships to disclose. B.E.J. reports consultant fees from Checkpoint Therapeutics, Genentech, Hummingbird Diagnostics and Hengrui Therapeutics. J.M.L. reports grants, consulting fees and honoraria from AstraZeneca, Bristol Myers Squibb, Genentech and Novartis and leadership roles at AstraZeneca, Genentech and Novartis. G.L. reports research funding from Genentech, Innate Pharma, Novartis and Stemline Therapeutics. M.P. reports no relationships to disclose. M.S. reports no relationships to disclose. W.Y.B. reports no relationships to disclose. K.S. is an employee of Genentech and reports stock ownership with Roche. A.N. is an employee of Genentech and reports stock ownership with Roche. A.J. is an employee of Genentech and reports stock ownership with Roche. J.G. is an employee of Genentech and reports stock ownership with Roche. S.H. is an employee of Genentech and reports stock ownership with Roche. D.S. is an employee of Genentech and reports stock ownership with Roche. C.R. reports no relationships to disclose. E.T. reports honoraria from Intuitive Surgical. E.B.H. serves in a consulting or advisory role to Amgen, Ellipses Pharma, Janssen Oncology, Janssen Research & Development and Revolution Medicines; reports research funding (paid to his institution) from AstraZeneca, Genentech, Incyte, Janssen, Novartis, Revolution Medicines and Spectrum Pharmaceuticals; and reports patents, royalties or other intellectual property from Protein–Protein Interactions as Biomarkers Patent. C.J.M. reports no relationships to disclose. G.A.P. reports no relationships to disclose. S.N.W. reports research support grants from AbbVie, Ariad Pharmaceuticals, Genentech, Immunomedics, Millennium Pharmaceuticals, Roche, Astellas Pharma, Daiichi Sankyo, Cullinan Pearl, Verastem, GlaxoSmithKline/GSK, Janssen Research & Development, Elevation Oncology, Genentech, Loxo Oncology, Takeda Pharmaceuticals Company Limited and the SWOG Clinical Trials Partnership; has received honoraria from the American Society of Clinical Oncology; and serves as Chair of the Data Safety Monitoring Board for the Hoosier Cancer Research Network. V.W.R. is a member of the Data Safety and Monitoring Committee for the MARS2 trial (UK) and serves as Co-Chair of the National Cancer Institute Thoracic Staging Malignancy Committee. She reports funding (paid to her institution) from Genentech. D.P.C. serves in a consultant or advisory role to AbbVie, Agenus, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, EMD Serono, Genentech/Roche, Helsinn Healthcare, Incyte, Inivata, Inovio Pharmaceuticals, Janssen, Kyowa Hakko Kirin, Merck, Novartis, Pfizer, prIME Oncology and Takeda and research funding from Bristol Myers Squibb and Genentech.